OBJECTIVE: Physical function impairments are seen among aging, HIV-infected persons on effective antiretroviral therapy (ART). The impact of physical function impairments on health-related quality of life (QoL) during ART is unknown. DESIGN: This was a cross-sectional study including 359 HIV-infected patients, aged 45-65 years, on ART for more than 6 months. METHODS: Patients completed the SF-36 QoL questionnaire, 400-m walk, 5-time chair rise, and grip strength. HIV-associated mortality risk was calculated using the Veterans Aging Cohort Study (VACS) Index. Physical function, physical activity (> 500 versus ≤ 500 kcal/week), and VACS scores were used to estimate QoL in multivariable linear regression. RESULTS: For every 1 m/s increase in gait speed, we saw an estimated 11.8 [95% confidence interval (CI) 8.4, 15.2] point increase in the physical function scale with smaller differences across all subscales. For every 1 rise/s faster chair rise pace, we saw an estimated 16.0 (95% CI 9.1, 22.9) point increase in the physical function scale with smaller differences across all subscales. SF-36 scores were between 2.8 and 5.7 points higher among more physically active compared to less active patients. A 1 kg increase in grip strength was associated with a 0.2 (95% CI 0.01, 0.3) higher mental health score, but there were no differences in other subscales. VACS scores did not improve the model. CONCLUSIONS: Faster gait speed and chair rise time, and greater physical activity were associated with greater QoL, independent of HIV-related mortality risk. Targeted exercise programs to increase physical activity and improve speed and power should be evaluated as interventions to improve QoL during ART.
OBJECTIVE: Physical function impairments are seen among aging, HIV-infectedpersons on effective antiretroviral therapy (ART). The impact of physical function impairments on health-related quality of life (QoL) during ART is unknown. DESIGN: This was a cross-sectional study including 359 HIV-infectedpatients, aged 45-65 years, on ART for more than 6 months. METHODS:Patients completed the SF-36 QoL questionnaire, 400-m walk, 5-time chair rise, and grip strength. HIV-associated mortality risk was calculated using the Veterans Aging Cohort Study (VACS) Index. Physical function, physical activity (> 500 versus ≤ 500 kcal/week), and VACS scores were used to estimate QoL in multivariable linear regression. RESULTS: For every 1 m/s increase in gait speed, we saw an estimated 11.8 [95% confidence interval (CI) 8.4, 15.2] point increase in the physical function scale with smaller differences across all subscales. For every 1 rise/s faster chair rise pace, we saw an estimated 16.0 (95% CI 9.1, 22.9) point increase in the physical function scale with smaller differences across all subscales. SF-36 scores were between 2.8 and 5.7 points higher among more physically active compared to less active patients. A 1 kg increase in grip strength was associated with a 0.2 (95% CI 0.01, 0.3) higher mental health score, but there were no differences in other subscales. VACS scores did not improve the model. CONCLUSIONS: Faster gait speed and chair rise time, and greater physical activity were associated with greater QoL, independent of HIV-related mortality risk. Targeted exercise programs to increase physical activity and improve speed and power should be evaluated as interventions to improve QoL during ART.
Authors: M A Pereira; S J FitzerGerald; E W Gregg; M L Joswiak; W J Ryan; R R Suminski; A C Utter; J M Zmuda Journal: Med Sci Sports Exerc Date: 1997-06 Impact factor: 5.411
Authors: Avan Aihie Sayer; Holly E Syddall; Helen J Martin; Elaine M Dennison; Helen C Roberts; Cyrus Cooper Journal: Age Ageing Date: 2006-05-11 Impact factor: 10.668
Authors: Krisann K Oursler; Joseph L Goulet; David A Leaf; Ayse Akingicil; Leslie I Katzel; Amy Justice; Stephen Crystal Journal: AIDS Patient Care STDS Date: 2006-11 Impact factor: 5.078
Authors: Anne B Newman; Eleanor M Simonsick; Barbara L Naydeck; Robert M Boudreau; Stephen B Kritchevsky; Michael C Nevitt; Marco Pahor; Suzanne Satterfield; Jennifer S Brach; Stephanie A Studenski; Tamara B Harris Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Loic Desquilbet; Lisa P Jacobson; Linda P Fried; John P Phair; Beth D Jamieson; Marcy Holloway; Joseph B Margolick Journal: J Gerontol A Biol Sci Med Sci Date: 2007-11 Impact factor: 6.053
Authors: Amanda A Allshouse; Sam MaWhinney; Catherine M Jankowski; Wendy M Kohrt; Thomas B Campbell; Kristine M Erlandson Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Mary Clare Masters; Jeremiah Perez; Katherine Tassiopoulos; Adriana Andrade; Ronald Ellis; Jingyan Yang; Todd T Brown; Frank J Palella; Kristine M Erlandson Journal: AIDS Res Hum Retroviruses Date: 2019-09-30 Impact factor: 2.205
Authors: Dana Rose Garfin; Sanghyuk S Shin; Maria L Ekstrand; Kartik Yadav; Catherine L Carpenter; Sanjeev Sinha; Adeline M Nyamathi Journal: AIDS Care Date: 2019-02-03
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Krupa N Shah; Zahraa Majeed; Yilmaz B Yoruk; Hongmei Yang; Tiffany N Hilton; James M McMahon; William J Hall; Donna Walck; Amneris E Luque; Richard M Ryan Journal: Health Psychol Date: 2016-02-11 Impact factor: 4.267